Contineum Therapeutics Inc

For the period ended Dec 31, 2024. Filed Mar 6, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 6, 2025

CTNM$10.56+2.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of Operations and Comprehensive Income (Loss)

(in thousands, except share and per share data)

	Years Ended December 31,
	2024	2023
Revenue
License revenue	$—	$50,000
Operating expenses:
Research and development	38,422	27,603
General and administrative	12,472	6,320
Total operating expenses	50,894	33,923
Income (loss) from operations	(50,894)	16,077
Other income (expense):
Interest income	8,905	4,606
Interest expense	—	(208)
Change in fair value of warrant liability	(106)	5
Change in fair value of investor rights and obligations liability	—	2,867
Other expense, net	(163)	(177)
Total other income, net	8,636	7,093
Income (loss) before income taxes	(42,258)	23,170
Provision for income taxes	—	450
Net income (loss)	$(42,258)	$22,720
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities	(37)	184
Comprehensive income (loss)	$(42,295)	$22,904
Net income (loss) attributable to common stockholders, basic	$(42,258)	$3,146
Net income (loss) attributable to common stockholders, diluted	$(42,258)	$274
Net income (loss) per share, basic (a)	$(2.18)	$1.36
Net income (loss) per share, diluted (a)	$(2.18)	$0.08
Weighted-average common shares outstanding, basic	19,352,859	2,308,972
Weighted-average common shares outstanding, diluted	19,352,859	3,395,514

(a)	Basic and diluted per share amounts are the same for Class A and Class B shares.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.